A number of other TRAIL bispecific constructs selective for the albumin binding domain ABD [179], annexin V [180], CM4, a small cationic linear α-helical peptide selective for tumor cells [181], Fn14 [182], integrins RGD [183,184,185] and iRGD [186], tumor molecular targeted peptide 1 (TMTP1) [187], or vasostatin (VAS) [188], have also been described, including a trispecific recombinant TRAIL protein harboring both an RGD- and an NGR-binding motif [189], all of which bind more or less specifically to tumor cells, and displaying increased TRAIL-mediated apoptosis rates. The gene discussed is ALB; the disease is neoplasm.